The current financial score of Burning Rock Biotech Ltd is 7.67. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 20.10M, representing a year-over-year decrease of 3.56%, while its net profit experienced a year-over-year decrease of 101.73%.
The current valuation score of Burning Rock Biotech Ltd is 9.76. Its current P/E ratio is -19.12, which is -102.04% below the recent high of 0.39 and -60.36% above the recent low of -30.66.
No earnings forecast score is currently available for Burning Rock Biotech Ltd. The Healthcare Providers & Services industry's average is 7.67.
The current price momentum score of Burning Rock Biotech Ltd is 7.50. Currently, the stock price is trading between the resistance level at 15.94 and the support level at 10.82, making it suitable for range-bound swing trading.
The current institutional shareholding score of Burning Rock Biotech Ltd is 3.00. The latest institutional shareholding proportion is 45.78%, representing a quarter-over-quarter decrease of 1.69%. The largest institutional shareholder is James Simons, holding a total of 52.84K shares, representing 0.00% of shares outstanding, with 181.94% increase in holdings.
The current risk assessment score of Burning Rock Biotech Ltd is 2.11. The company's beta value is 1.38. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.